Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
866 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT07049276 | The Multicentre Selective Lymphadenectomy Trial - 3(MSLT-3) | recruiting | N/A | 1,500 | Melanoma Institute AustraliaOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT07670858 | Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC) | recruiting | Phase 1 | 48 | Feldan TherapeuticsINDUSTRY | 2 | Jun 29, 2026 | clinicaltrials |
| NCT04614103 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | recruiting | Phase 2 | 170 | Iovance Biotherapeutics, Inc.INDUSTRY | 12 | Jun 26, 2026 | clinicaltrials |
| NCT05009992 | Combination Therapy for the Treatment of Diffuse Midline Gliomas(PNOC022) | recruiting | Phase 2 | 360 | University of California, San FranciscoOTHER | 6 | Jun 26, 2026 | clinicaltrials |
| NCT06598306 | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)(DeLLphi-308) | recruiting | Phase 1 | 220 | AmgenINDUSTRY | 10 | Jun 26, 2026 | clinicaltrials |
| NCT06220864 | SNV1521 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 400 | Synnovation Therapeutics, Inc.INDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | recruiting | Phase 1 | 675 | GlaxoSmithKlineINDUSTRY | 15 | Jun 25, 2026 | clinicaltrials |
| NCT05653388 | Metastatic Leiomyosarcoma Biomarker Protocol | recruiting | — | 200 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | recruiting | Phase 1 / Phase 2 | 70 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation(ELAINEIII) | recruiting | Phase 3 | 600 | LeonaBioINDUSTRY | 17 | Jun 22, 2026 | clinicaltrials |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | recruiting | Phase 3 | 400 | Ascentage Pharma Group Inc.INDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | recruiting | Phase 3 | 180 | Vor BiopharmaINDUSTRY | 14 | Jun 18, 2026 | clinicaltrials |
| NCT07215585 | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL(SOUNDTRACK-D2) | recruiting | Phase 3 | 420 | AstraZenecaINDUSTRY | 11 | Jun 18, 2026 | clinicaltrials |
| NCT05093231 | Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | recruiting | Phase 2 | 20 | Cambridge University Hospitals NHS Foundation TrustOTHER | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT04643002 | Isatuximab in Combination With Novel Agents in RRMM - Master Protocol | recruiting | Phase 1 / Phase 2 | 258 | SanofiINDUSTRY | 10 | Jun 16, 2026 | clinicaltrials |
| NCT05208047 | (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | recruiting | Phase 3 | 482 | Cogent Biosciences, Inc.INDUSTRY | 22 | Jun 16, 2026 | clinicaltrials |
| NCT06253130 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Eikon TherapeuticsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT06940739 | A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel | recruiting | Phase 1 / Phase 2 | 42 | Iovance Biotherapeutics, Inc.INDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 375 | BioNTech SEINDUSTRY | 2 | Jun 15, 2026 | clinicaltrials |
| NCT05950945 | Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | recruiting | Phase 3 | 250 | Daiichi SankyoINDUSTRY | 10 | Jun 12, 2026 | clinicaltrials |
| NCT07640425 | Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture | recruiting | Phase 1 / Phase 2 | 60 | CONNEXTINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT06050707 | MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach(MAESTRO) | recruiting | Phase 2 | 80 | University Health Network, TorontoOTHER | 3 | Jun 10, 2026 | clinicaltrials |
| NCT06631872 | Implementing Surgery School Prehabilitation Using Telehealth(STTARRS) | recruiting | N/A | 515 | University of MelbourneOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07608848 | First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer(DOTA-STR-17126) | recruiting | Early Phase 1 | 20 | Integrated Haematology and Oncology NetworkOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639047 | An Initial Evaluation of AN8025 in Solid Tumors | recruiting | Phase 1 | 91 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02821013 | Duration of Anti-PD-1 Therapy in Metastatic Melanoma(STOP-GAP) | recruiting | Phase 3 | 614 | Canadian Cancer Trials GroupNETWORK | 2 | Jun 9, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07238075 | ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers | recruiting | Phase 1 | 290 | Adcytherix SASINDUSTRY | 2 | Jun 8, 2026 | clinicaltrials |
| NCT06554795 | First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | DualityBio Inc.INDUSTRY | 3 | Jun 5, 2026 | clinicaltrials |
| NCT07628751 | A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC(SOCRATES HCC) | recruiting | N/A | 218 | University Health Network, TorontoOTHER | 2 | Jun 5, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK | 25 | Jun 4, 2026 | clinicaltrials |
| NCT07465796 | A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma(CIPHER) | recruiting | N/A | 10 | Coherence Neuro Australia Pty LimitedINDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07612280 | Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis | recruiting | Phase 1 / Phase 2 | 30 | Jubilant Therapeutics Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06815575 | A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours. | recruiting | Phase 1 | 53 | Racura Oncology LtdINDUSTRY | 3 | Jun 2, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT06372717 | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | recruiting | Phase 1 | 100 | Apollo Therapeutics LtdINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 6 | May 29, 2026 | clinicaltrials |
| NCT06153667 | Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)(BETTER-UAE) | recruiting | — | 100 | Merit Medical Systems, Inc.INDUSTRY | 3 | May 29, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07258407 | A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 180 | T.O.A.D. Oncology SAINDUSTRY | 5 | May 29, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | recruiting | Phase 1 / Phase 2 | 840 | Nuvalent Inc.INDUSTRY | 15 | May 27, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT07541391 | Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease(KOALA) | recruiting | Phase 1 | 12 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials